Ghrelin Receptor (GHSR): The Growth Hormone Secretagogue Receptor

The growth hormone secretagogue receptor (GHS-R1a), commonly called the ghrelin receptor or GHSR, is a G protein-coupled receptor (GPCR) that mediates growth hormone release from the anterior pituitary and appetite signaling from the hypothalamus. It is the molecular target of endogenous ghrelin and all synthetic GH secretagogues — ipamorelin, GHRP-2, GHRP-6, hexarelin, and the non-peptide agonist MK-677.

Receptor structure and signaling

GHSR is a seven-transmembrane GPCR encoded by the GHSR gene on chromosome 3q26. Two splice variants exist:

• GHS-R1a: The full-length, functionally active receptor. This is what "ghrelin receptor" refers to in pharmacological contexts.
• GHS-R1b: A truncated, five-transmembrane variant with no known signaling activity but potential regulatory function through heterodimerization with GHS-R1a.

Primary signaling cascade

When ghrelin or a GH secretagogue binds GHS-R1a on pituitary somatotrophs:

1. Gq/11 coupling: The receptor activates Gq/11, which stimulates phospholipase C (PLC)
2. IP3 and DAG production: PLC cleaves PIP2 into IP3 and diacylglycerol (DAG)
3. Calcium release: IP3 triggers calcium release from the endoplasmic reticulum
4. GH exocytosis: Elevated intracellular calcium triggers growth hormone vesicle fusion with the plasma membrane and GH secretion

This calcium-dependent mechanism is distinct from GHRH signaling (which operates through Gs/cAMP). The two pathways are synergistic — combining a GH secretagogue with GHRH (or CJC-1295) produces a GH pulse larger than either alone.

Constitutive activity

GHSR has unusually high constitutive (basal) activity — approximately 50% of its maximal signaling occurs without any ligand bound. This means the receptor is always partially "on." This constitutive activity contributes to baseline appetite signaling and tonic GH regulation. Inverse agonists that suppress this basal activity have been investigated as appetite suppressants.

Tissue distribution and functions

Anterior pituitary

The highest density of functional GHSR is on pituitary somatotrophs. Activation here drives pulsatile GH release. This is the primary pharmacological target of GH secretagogues.

Hypothalamus

GHSR expression in the arcuate nucleus mediates ghrelin's orexigenic (appetite-stimulating) effect. Ghrelin activates NPY/AgRP neurons while inhibiting POMC/CART neurons, increasing hunger signaling. This is why GHRP-6 — which binds GHSR with less selectivity — causes pronounced hunger, while ipamorelin — designed for more selective pituitary GHSR activation — produces less appetite stimulation.

Other tissues

• Hippocampus: GHSR activation enhances synaptic plasticity and long-term potentiation. Ghrelin and GH secretagogues may have nootropic effects through this mechanism.
• Cardiovascular system: GHSR is expressed in cardiomyocytes. Hexarelin shows cardioprotective effects that may be partially GHSR-mediated (though hexarelin also binds CD36).
• Immune cells: GHSR expression on T cells and macrophages suggests a role in immunomodulation.

GH secretagogues: binding and selectivity

| Compound | GHSR Binding | Selectivity | Notable Off-Target Activity |

|----------|-------------|-------------|----------------------------|

| Ghrelin | Endogenous ligand | Physiological | Full appetite, GH, cardiovascular effects |

| Ipamorelin | High affinity | High (GHSR-selective) | Minimal cortisol/prolactin stimulation |

| GHRP-6 | High affinity | Moderate | Appetite stimulation, some cortisol elevation |

| GHRP-2 | High affinity | Moderate | Strongest GH release, some cortisol/prolactin |

| Hexarelin | High affinity | Lower | CD36 binding (cardioprotective), cortisol, prolactin |

| MK-677 | High affinity (non-peptide) | Moderate | Sustained GH elevation (oral, long half-life) |

Ipamorelin's selectivity advantage is clinically significant: it activates GHSR on somatotrophs without meaningfully stimulating ACTH release (cortisol) or prolactin secretion, making it the cleanest GH secretagogue for isolated GH pulsing.

Desensitization and cycling

Repeated GHSR activation triggers the standard GPCR desensitization cascade:

1. GRK phosphorylation: G protein-coupled receptor kinases phosphorylate the activated receptor
2. Beta-arrestin recruitment: Blocks further G protein coupling
3. Receptor internalization: GHSR is endocytosed, reducing surface receptor density
4. Downregulation: Prolonged agonism decreases GHSR gene expression

The rate of desensitization varies by compound. Hexarelin desensitizes GHSR faster than ipamorelin — likely because hexarelin's broader receptor engagement recruits additional desensitization pathways. This is why hexarelin cycles are typically 4-6 weeks while ipamorelin can be used for 12-16 weeks before requiring a washout.

Pulsatile dosing (once or twice daily rather than continuous infusion) partially mitigates desensitization by allowing receptor resensitization between doses. This mimics the natural pattern of pulsatile ghrelin secretion and is a key reason GH secretagogues are dosed as discrete injections rather than as sustained-release formulations.

GHSR and the fasting requirement

Elevated insulin suppresses GH secretagogue-induced GH release through multiple mechanisms — including direct inhibition of somatotroph signaling and enhanced somatostatin tone. Because GHSR signaling and insulin signaling converge at overlapping intracellular pathways, administering GH secretagogues in a fasted state (at least 2 hours post-meal, ideally before bed or upon waking) maximizes the GH pulse amplitude. This is not optional protocol optimization — it is a pharmacological requirement for meaningful GH release.